Compare WNEB & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WNEB | IMRX |
|---|---|---|
| Founded | 1853 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.8M | 288.6M |
| IPO Year | 2001 | 2021 |
| Metric | WNEB | IMRX |
|---|---|---|
| Price | $13.81 | $5.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $13.67 | ★ $17.20 |
| AVG Volume (30 Days) | 49.6K | ★ 602.4K |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | 33.93 | ★ 37.75 |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $44,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.25 | N/A |
| P/E Ratio | $32.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.78 | $3.86 |
| 52 Week High | $15.01 | $10.08 |
| Indicator | WNEB | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.32 | 56.89 |
| Support Level | $13.28 | $4.82 |
| Resistance Level | $13.96 | $5.38 |
| Average True Range (ATR) | 0.25 | 0.22 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 38.85 | 68.18 |
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.